z-logo
open-access-imgOpen Access
The Discovery of Macrocyclic XIAP Antagonists from a DNA-Programmed Chemistry Library, and Their Optimization To Give Lead Compounds with in Vivo Antitumor Activity
Author(s) -
Benjamin A. Seigal,
William H. Connors,
Andrew W. Fraley,
R. M. Borzilleri,
Percy H. Carter,
Stuart L. Emanuel,
Joseph Fargnoli,
Kyoung Kim,
Ming Lei,
Joseph G. Naglich,
Matthew Pokross,
Shana L. Posy,
Henry Shen,
Neha Surti,
Randy Talbott,
Yong Zhang,
N.K. Terrett
Publication year - 2015
Publication title -
journal of medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.01
H-Index - 261
eISSN - 1520-4804
pISSN - 0022-2623
DOI - 10.1021/jm501892g
Subject(s) - xiap , chemistry , in vivo , apoptosis , cocrystal , lead compound , inhibitor of apoptosis , dna , combinatorial chemistry , caspase , in vitro , stereochemistry , cancer research , programmed cell death , biochemistry , molecule , genetics , hydrogen bond , organic chemistry , biology
Affinity selection screening of macrocycle libraries derived from DNA-programmed chemistry identified XIAP BIR2 and BIR3 domain inhibitors that displace bound pro-apoptotic caspases. X-ray cocrystal structures of key compounds with XIAP BIR2 suggested potency-enhancing structural modifications. Optimization of dimeric macrocycles with similar affinity for both domains were potent pro-apoptotic agents in cancer cell lines and efficacious in shrinking tumors in a mouse xenograft model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom